Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study

Gastroenterology

Volumn 133, Issue 1, 2007, Pages 57-64

  Hawkey, Christopher J ^a   Weinstein, Wilfred M ^b   Smalley, Walter ^c   Gitton, Xavier ^d   Sallstig, Peter ^d   Stricker, Kirstin ^d   Krammer, Gerhard ^d   Mellein, Bernhard ^d   Richard, Dominik ^d   Matchaba, Patrice ^d  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LUMIRACOXIB;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG USE; DUODENUM ULCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STOMACH ULCER;

EID: 34447106922     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.04.045     Document Type: Article

References (21)

1. American College of Rheumatology, American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43 (2000) 1905-1915
2. Pendleton A., Arden N., Dougados M., Doherty M., Bannwarth B., Bijlsma J.W., Cluzeau F., Cooper C., Dieppe P.A., Gunther K.P., Hauselmann H.J., Herrero-Beaumont G., Kaklamanis P.M., Leeb B., Lequesne M., Lohmander S., Mazieres B., Mola E.M., Pavelka K., Serni U., Swoboda B., Verbruggen A.A., Weseloh G., and Zimmerman-Gorska I. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic trials (ESCISIT). Ann Rheum Dis 59 (2000) 936-944
3. Singh G., Ramey D.R., Morfeld D., Shi H., Hatoum H.T., and Fries J.F. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 156 (1996) 1530-1536
4. Hawkey C.J., and Langman M.J. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52 (2003) 600-608
5. Esser R., Berry C., Du Z., Dawson J., Fox A., Fujimoto R.A., Haston W., Kimble E.F., Koehler J., Peppard J., Quadros E., Quintavalla J., Toscano K., Urban L., van Duzer J., Zhang X., Zhou S., and Marshall P.J. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144 (2005) 538-550
6. Rordorf C.M., Choi L., Marshall P., and Mangold J.B. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 44 (2005) 1247-1266
7. Weaver M.L., Flood D.J., Kimble E.F., and Fujimoto R.A. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors. (abstr). Ann Rheum Dis 62 Suppl I (2003) 378
8. Scott G., Rordorf C., Reynolds C., Kalbag J., Looby M., Milosavljev S., Weaver M., Huff J.P., and Ruff D.A. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 43 (2004) 467-478
9. Hawkey C.J., Farkouh M., Gitton X., Ehrsam E., Huels J., and Richardson P. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib-study design and patient demographics. Aliment Pharmacol Ther 20 (2004) 51-63
10. Laine L., Bombardier C., Hawkey C.J., Davis B., Shapiro D., Brett C., and Reicin A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123 (2002) 1006-1012
11. Garcia Rodriguez L.A., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 769-772
12. Hansen J.M., Hallas J., Lauritsen J.M., and Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 31 (1996) 126-130
13. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., Gimona A., Hawkey C.J., and TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
14. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
15. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., and Geis G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
16. Hawkey C.J., Naesdal J., Wilson I., Langstrom G., Swannell A.J., Peacock R.A., and Yeomans N.D. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 3 (2002) 336-343
17. Hawkey C.J., Wilson I., Naesdal J., Langstrom G., Swannell A.J., and Yeomans N.D. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 51 (2002) 344-350
18. Jackson L.M., Wu K.C., Mahida Y.R., Jenkins D., and Hawkey C.J. Cyclooxygenase (COX) 1 and 2 in normal, inflamed and ulcerated human gastric mucosa. Gut 47 (2000) 762-770
19. Poonam D., Vinay C.S., and Gautam P. Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing. Eur J Pharmacol 519 (2005) 277-284
20. Rahme E., Bardou M., Dasgupta K., Toubouti Y., Ghosn J., and Barkun A.N. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 46 (2007) 265-272 [Epub ahead of print]
21. Goldstein J.L., Lowry S.C., Lanza F.L., Schwartz H.I., and Dodge W.E. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 23 (2006) 1489-1498